weight loss market

Amazon launches GLP-1 weight management program through One Medical, leveraging its healthcare ecosystem and logistics capabilities to tap into a market projected to reach nearly $100 billion by 2030.

Pfizer's experimental monthly GLP-1 injection threatens to disrupt the weight-loss market dominated by Novo Nordisk and Eli Lilly, potentially triggering price competition.

Eli Lilly's obesity pill logged 1,390 first-week prescriptions versus Novo Nordisk's 3,071 in four days, as $NVO maintains commanding 113,354 weekly Wegovy prescriptions.

$VKING develops competing obesity drugs against $LLY and $NVO, with oral candidate entering phase 3 trials in Q3 2026 amid projected $100B market expansion.

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.

Oral weight-loss drugs expand the market rather than cannibalizing injectables, attracting new patients. However, Novo Nordisk expects 2026 revenue headwinds from competition and pricing pressures.